Stock Alert: Humanigen Climbs 30% After Positive News On Its Lenzilumab

(RTTNews) - Shares of clinical-stage biopharmaceutical company, Humanigen, Inc. (HGEN) jumped more than 30% Tuesday morning and touched a new high of $6.79.

Monday, Humanigen said that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) has selected Lenzilumab, the company's late-stage drug candidate in Covid-19 for Big Effect Trial (BET) in SARS-CoV-2 infected patients.

Lenzilumab will be evaluated in combination with Gilead Sciences' remdesivir and compared to placebo and remdesivir.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More